---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-26-000004"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:51:58.081866+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Guardant Health reports Q4 revenue $280M (+39% YoY); full year revenue $981M (+33%)

## Summary
- Q4 oncology tests ~79,000 (+38% YoY); full year ~276,000 (+34%).
- Shield screening tests surged to ~38,000 in Q4 (vs 6,400 prior year).
- Preliminary free cash flow: -$54M Q4, -$233M full year.
- Cash and marketable securities ~$1.3B as of Dec 31, 2025.
- Results are preliminary and unaudited; final audited results expected Feb 2026.

## SEC filing metadata
- accession: 0001576280-26-000004
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628026000004/0001576280-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628026000004/gh-20260111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-26-000004
- JSON: https://secwatch.observer/filing/0001576280-26-000004.json
- Plain text: https://secwatch.observer/filing/0001576280-26-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.